Shares of Acadia closed yesterday at $31.96 . ACAD has a 1-year high of $46.48 and a 1-year low of $15.64. The stock's 50-day moving average is $35.90 and it's 200-day moving average is $30.99.
On the ratings front, Acadia has been the subject of a number of recent research reports. In a report issued on March 12, J.P. Morgan analyst Cory Kasimov reiterated a Buy rating on ACAD, with a price target of $40, which implies an upside of 25.2% from current levels. Separately, on the same day, Needham's Alan Carr reiterated a Buy rating on the stock and has a price target of $38.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Cory Kasimov and Alan Carr have a total average return of 8.3% and 42.0% respectively. Kasimov has a success rate of 46.3% and is ranked #788 out of 3568 analysts, while Carr has a success rate of 72.7% and is ranked #6.
The street is mostly Bullish on ACAD stock. Out of 5 analysts who cover the stock, 5 suggest a Buy rating . The 12-month average price target assigned to the stock is $42.80, which implies an upside of 33.9% from current levels.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of small molecule drugs for the treatment of central nervous system disorders.